Cogent Biosciences, Inc.

COGTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1622229

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$173.8M	$121.6M	$55.9M	$55.9M	$25.7M
Operating Income (Loss)	-$208.1M	-$147.8M	-$75.6M	-$75.6M	-$82.2M
Nonoperating Income (Expense)	$15.7M	$7.6M	$3.3M	$3.3M	$7.4M
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$192.4M	-$140.2M	-$72.3M	-$72.3M	-$74.8M
Earnings Per Share, Basic	-$1.94	-$1.73	-$1.87	-$1.87	—
Earnings Per Share, Diluted	-$1.94	-$1.73	-$1.87	-$1.87	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$327.9M	$313.4M	$300.8M	$232.1M	$250.9M
Assets, Current	$296.5M	$270.8M	$265.0M	$222.6M	$244.9M
Cash and Cash Equivalents, at Carrying Value	$98.2M	$53.2M	$139.9M	$219.7M	$242.2M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities	$71.6M	$55.6M	$45.1M	$17.9M	$16.2M
Liabilities, Current	$55.7M	$38.2M	$26.8M	$17.1M	$13.1M
Long-term Debt	$222.9M	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$153.6M	-$118.6M	-$58.8M	-$58.8M	-$35.9M
Net Cash Provided by (Used in) Investing Activities	-$97.8M	-$124.7M	-$1.7M	-$1.7M	$8.4M
Net Cash Provided by (Used in) Financing Activities	$163.5M	$163.6M	$38.0M	$38.0M	$232.2M
Payments to Acquire Property, Plant, and Equipment	$2.8M	$6.9M	$1.7M	$1.7M	$1.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)